On February 21, 2002, Sun Pharm Industries announced the approval of generic drug application ANDA076038, subjecting the prescription to generic competition immediately. Investor focus will shift to market share gains and revenue ramp-up, as the launch stands to erode the profitability of the branded analogous drug.